Last Updated: May 4, 2026

Litigation Details for National Steel Car Limited v. Greenbrier-Concarril LLC (D. Or. 2020)


✉ Email this page to a colleague

« Back to Dashboard


National Steel Car Limited v. Greenbrier-Concarril LLC (D. Or. 2020)

Docket 3:20-cv-01275 Date Filed 2020-08-03
Court District Court, D. Oregon Date Terminated 2024-01-03
Cause 35:271 Patent Infringement Assigned To Youlee Yim You
Jury Demand Both Referred To
Patents 12,168,021; 6,011,068; 8,106,022; 8,217,007
Link to Docket External link to docket
Small Molecule Drugs cited in National Steel Car Limited v. Greenbrier-Concarril LLC
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation summary and analysis for: National Steel Car Limited v. Greenbrier-Concarril LLC (D. Or. 2020)

Last updated: April 25, 2026

What happened in National Steel Car Limited v. Greenbrier-Concarril LLC, 3:20-cv-01275?

What is the case and what posture does the docket show?

  • Court / Case number: U.S. District Court, 3:20-cv-01275
  • Parties: National Steel Car Limited (plaintiff) v. Greenbrier-Concarril LLC (defendant)
  • Core litigation objective (as reflected by the case caption and typical asserted IP posture in this matter): enforcement of patent rights tied to railcar technology.

Actionable read-through for business decisions: The docket posture indicates a proceeding in federal court in which the plaintiff sought relief on patent claims; the litigation history should be evaluated on (1) claim construction and dispositive motion outcomes, and (2) any damages or injunction-related rulings. Without the actual docket entries and order texts, a definitive merits or outcome summary cannot be produced.

What claims were asserted and what defenses were raised?

No claim set, asserted patent numbers, independent claims, or defenses (non-infringement, invalidity, unenforceability, indefiniteness, etc.) are stated in the information provided to this analysis. Without the complaint, claim charts, motion papers, or court orders, any attempt to specify asserted claims, filing dates, or legal theories would be non-factual.

What events drive the litigation timeline?

A reliable timeline requires docket-specific events (complaint filing, service, amended complaints, Markman scheduling, claim construction orders, summary judgment orders, trial dates, settlement notices, and final judgment). Those items are not available in the current input.


Why does the litigation matter for patent strategy and exposure?

What is the infringement and validity risk framework?

For U.S. patent cases, business exposure usually concentrates in three decision nodes:

  1. Claim construction (sets the claim scope that the infringement and invalidity fights pivot on).
  2. Dispositive rulings (summary judgment on infringement/invalidity; posture for settlement).
  3. Remedies (injunction analysis, damages methodology, and apportionment).

In this case, none of those rulings are provided here, so there is no basis for mapping the actual risk profile to this particular docket.

How to use the court’s procedural history to estimate outcomes

Even without merits detail, federal patent cases tend to separate into two practical buckets:

  • Early settlements driven by Markman uncertainty or cost exposure.
  • Motion-heavy trajectories driven by invalidity and non-infringement positions.

Because the procedural record is not included, this case cannot be categorized with factual precision.


Litigation issue map (what typically gets decided in this docket type)

How do courts treat common infringement theories?

In railcar/patent disputes, infringement analysis often turns on:

  • Structural features (components, configurations, interfaces)
  • Functional relationships (how parts cooperate)
  • System-level architecture (assembly or subsystem integration)

No asserted feature set is available in the current input.

How do defendants typically attack patents like these?

Common validity and enforceability attack lines include:

  • Anticipation/obviousness over prior art (design, engineering drawings, product catalogs, and published patents)
  • Indefiniteness of claim boundaries
  • Non-enablement (for written description and enablement failures)
  • Best mode (rarely outcome-determinative now, but still asserted historically)

No prior art references or invalidity arguments are provided.


Settlement, injunction, and damages: what the business should focus on

Were there any remedy-related rulings?

No injunction, permanent injunction, preliminary injunction, damages, or accounting orders are provided in the current input.

Was there a final disposition?

No final judgment, dismissal order, or settlement filing is provided here. Without the docket or order text, a final disposition summary would be speculative.


Key takeaways

  • The current input does not include the docket entries, complaint allegations, asserted patent numbers, claim construction, dispositive rulings, or remedy orders for National Steel Car Limited v. Greenbrier-Concarril LLC (3:20-cv-01275).
  • A complete, accurate litigation summary and analysis cannot be produced from the information supplied.

FAQs

  1. What patents were asserted in 3:20-cv-01275?
    Not provided in the current input.

  2. Did the court issue a claim construction (Markman) order?
    Not provided in the current input.

  3. Were any summary judgment motions granted or denied?
    Not provided in the current input.

  4. Was there any injunction, damages, or accounting decision?
    Not provided in the current input.

  5. What was the final outcome of the case?
    Not provided in the current input.


References

[1] Not provided in the current input.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.